PharmaCyte Biotech (PMCB) Goodwill & Intangibles (2013 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Goodwill & Intangibles of $1.5 million for Q1 2026, little changed year-over-year from $1.5 million in Q1 2025, and little changed quarter-over-quarter from $1.5 million in Q4 2025.
PharmaCyte Biotech (PMCB) Goodwill & Intangibles (2013 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Goodwill & Intangibles for 14 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles changed 0.0% year-over-year to $1.5 million; the TTM figure through Jan 2026 stood at $1.5 million (changed 0.0% YoY), while the FY2025 annual figure was $1.5 million, changed 0.0% from the prior year.
- Goodwill & Intangibles was little changed at $1.5 million in Q1 2026 per PMCB's latest filing, from $1.5 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $3.5 million in Q1 2022 and bottomed at $1.5 million in Q2 2024.
- Historically, Goodwill & Intangibles has averaged $2.6 million across 5 years, with a median of $3.5 million in 2022.
- Annual changes were most pronounced in 2022 — Goodwill & Intangibles changed 0.0% — and 2024, when it tumbled 56.35%.
- PharmaCyte Biotech's Goodwill & Intangibles stood at $3.5 million in 2022, then changed by 0.0% to $3.5 million in 2023, then sank by 56.35% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
- Business Quant data shows PMCB's Goodwill & Intangibles at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 1.55 Mn |
| Oct 31, 2025 | 1.55 Mn |
| Jul 31, 2025 | 1.55 Mn |
| Apr 30, 2025 | 1.55 Mn |
| Jan 31, 2025 | 1.55 Mn |
| Oct 31, 2024 | 1.55 Mn |
| Jul 31, 2024 | 1.55 Mn |
| Apr 30, 2024 | 1.55 Mn |
| Jan 31, 2024 | 3.55 Mn |
| Oct 31, 2023 | 3.55 Mn |
| Jul 31, 2023 | 3.55 Mn |
| Apr 30, 2023 | 3.55 Mn |
| Jan 31, 2023 | 3.55 Mn |
| Oct 31, 2022 | 3.55 Mn |
| Jul 31, 2022 | 3.55 Mn |
| Apr 30, 2022 | 3.55 Mn |
| Jan 31, 2022 | 3.55 Mn |
| Oct 31, 2021 | 3.55 Mn |
| Jul 31, 2021 | 3.55 Mn |
| Apr 30, 2021 | 3.55 Mn |